Centene Corporation
CNC
$66.44
+3.99%
Centene Corporation is a managed care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and individual exchanges. As one of the largest Medicaid managed care providers in the U.S., Centene serves approximately 20 million medical members, with Medicaid representing about 64% of its membership. The current investor narrative centers on the company's turnaround story, as it navigates a membership slump in its Affordable Care Act business and implements cost-cutting measures, including voluntary staff buyouts, while benefiting from favorable Medicare payment updates from CMS.…
CNC
Centene Corporation
$66.44
Related headlines
CNC 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Centene Corporation's 12-month outlook, with a consensus price target around $65.17 and implied upside of -1.9% versus the current price.
Average Target
$65.17
0 analysts
Implied Upside
-1.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$40 - $80
Analyst target range
Centene is covered by 18 analysts, with a consensus recommendation of 'Buy' (mean rating 2.48 on a 1-5 scale where 1 is Strong Buy). The average target price is $65.17, implying a slight downside of -1.9% from the current price of $66.44. The distribution shows 10 Buy/Overweight ratings, 6 Hold/Neutral, and 2 Sell/Underweight, indicating a moderately bullish consensus. The target range spans from a low of $40.00 to a high of $80.00. The high target of $80.00 assumes successful margin recovery and membership stabilization, while the low target of $40.00 prices in continued operational struggles and potential regulatory headwinds. Recent ratings from major firms (Wells Fargo, RBC, Cantor Fitzgerald, JP Morgan, Mizuho, BofA, Morgan Stanley, Truist, Barclays, UBS) have been mostly neutral to positive, with no recent downgrades. The wide spread between low and high targets ($40 to $80) signals high uncertainty about the company's near-term performance, but the consensus leans bullish.
Drowning in data?
Find the real signal!
Bulls vs Bears: CNC Investment Factors
Centene presents a classic turnaround opportunity with strong revenue growth, massive free cash flow, and a deeply discounted valuation (PS 0.10x vs. industry 0.5x). However, the stock has already rallied 128% over the past year, and the average analyst target offers no upside from current levels. The bull case rests on continued margin recovery and membership stabilization, while the bear case highlights earnings volatility and ACA headwinds. The single most important tension is whether the company can sustain its profitability improvement (Q1 2026 net income of $1.54B) and avoid further impairments, as this will determine if the valuation discount narrows or widens. Currently, the evidence slightly favors the bull case given the strong cash flow and improving margins, but the limited upside to analyst targets warrants caution.
Bullish
- Strong Revenue Growth Trajectory: Centene's Q1 2026 revenue of $49.94 billion grew 7.1% year-over-year, with consistent sequential growth from $48.74B in Q2 2025. This steady expansion, driven by Medicaid and Medicare, supports the turnaround narrative.
- Massive Free Cash Flow Generation: TTM free cash flow stands at $6.35 billion, with Q1 2026 alone generating $3.4 billion. This strong cash generation provides ample liquidity for debt reduction, share buybacks, or reinvestment.
- Significant Valuation Discount: The trailing PS ratio of 0.10x is 80% below the healthcare plans industry average of 0.5x and near the bottom of its historical range (0.32x-1.48x). This deep discount implies substantial upside if earnings normalize.
- Improving Profitability Trajectory: Gross margin improved to 21.9% in Q1 2026 from 15.2% in Q4 2025, and net income swung to $1.54 billion from a -$1.10 billion loss. The company is on a clear path to sustained profitability.
Bearish
- Negative Trailing Net Income: TTM net income is -$0.33 per share, with a net margin of -3.4%. The company reported large losses in Q3 2025 (-$6.63B) and Q4 2025 (-$1.10B), indicating significant earnings volatility.
- ACA Membership Slump: Centene is implementing voluntary staff buyouts due to a significant loss in Affordable Care Act membership. This headwind pressures near-term revenue and signals competitive challenges in the exchange market.
- Limited Upside to Analyst Target: The average analyst target of $65.17 implies a -1.9% downside from the current price of $66.44. Even the high target of $80 offers only 20.4% upside, limiting near-term return potential.
- High Valuation Risk Near 52-Week High: At $66.44, the stock trades at 95.8% of its 52-week high of $69.36, with a 1-year gain of 128%. This suggests much of the turnaround optimism is already priced in, increasing vulnerability to disappointments.
CNC Technical Analysis
Centene's stock is in a powerful uptrend, with a 1-year price change of +128.0%, dramatically outperforming the S&P 500's +18.35%. The current price of $66.44 sits at 95.8% of its 52-week range ($25.08 to $69.36), indicating strong momentum near the highs. This positioning near the top of the range suggests bullish sentiment but also raises the risk of overextension, as the stock has already priced in significant optimism. Over the past 3 months, the stock has surged 74.1%, and over the past month, it has gained 9.6%, showing accelerating short-term momentum. This recent strength aligns with the longer-term uptrend, confirming a sustained bullish phase. The 1-month relative strength versus the S&P 500 is +9.25%, indicating strong stock-specific momentum. The stock's beta of 1.077 suggests slightly higher volatility than the market, but not extreme. The 52-week low of $25.08 provides a key support level, while the 52-week high of $69.36 acts as immediate resistance. A breakout above $69.36 would signal further upside, while a breakdown below recent support near $60 could indicate a trend reversal. The stock's volatility, as measured by its beta, is moderate, meaning it moves roughly in line with the market but with a slight amplification.
Beta
1.08
1.08x market volatility
Max Drawdown
-55.5%
Largest decline past year
52-Week Range
$25-$69
Price range past year
Annual Return
+128.0%
Cumulative gain past year
| Period | CNC Return | S&P 500 |
|---|---|---|
| 1m | +9.6% | -0.5% |
| 3m | +74.1% | +4.9% |
| 6m | +45.2% | +9.7% |
| 1y | +128.0% | +18.4% |
| ytd | +59.0% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CNC Fundamental Analysis
Centene's revenue trajectory shows steady growth, with Q1 2026 revenue of $49.94 billion, up 7.1% year-over-year from $46.62 billion in Q1 2025. The multi-quarter trend reveals consistent revenue expansion, with quarterly revenues of $49.94B (Q1 2026), $49.73B (Q4 2025), $49.69B (Q3 2025), and $48.74B (Q2 2025). Revenue is driven primarily by the Medicaid segment ($39.21B) and Commercial segment ($9.56B), though recent membership losses in ACA plans are a headwind. The growth trajectory supports the investment case, but deceleration from prior double-digit growth rates warrants monitoring. Profitability has been volatile: Q1 2026 net income was $1.54 billion, a sharp recovery from losses in prior quarters (Q4 2025: -$1.10B, Q3 2025: -$6.63B). Gross margin improved to 21.9% in Q1 2026 from 15.2% in Q4 2025, indicating better cost management. However, the trailing twelve-month net margin is negative at -3.4%, reflecting the impact of prior impairments. The company is on a path to sustained profitability, but margin expansion needs to continue. Centene's balance sheet is solid: debt-to-equity ratio of 0.94 and current ratio of 1.68 indicate manageable leverage and adequate liquidity. Free cash flow generation is strong, with TTM FCF of $6.35 billion and Q1 2026 FCF of $3.4 billion. The company has $20.59 billion in cash, providing ample cushion. ROE is negative (-33.4%) due to prior losses, but the improving earnings trajectory should restore positive ROE. The strong FCF yield (FCF/EV) supports the investment case, indicating the company can fund operations internally.
Quarterly Revenue
$49.9B
2026-03
Revenue YoY Growth
+7.1%
YoY Comparison
Gross Margin
21.9%
Latest Quarter
Free Cash Flow
$6.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CNC Overvalued?
Given that Centene's trailing net income is negative (TTM net income of -$0.33 per share), the price-to-sales (PS) ratio is the primary valuation metric. The trailing PS ratio is 0.10x, while the forward PS (based on estimated revenue) is approximately 0.09x, implying the market expects continued revenue growth. The gap between trailing and forward PS is minimal, suggesting stable revenue expectations. Compared to the healthcare plans industry average PS ratio (approximately 0.5x), Centene trades at a significant discount of about 80%. This discount is likely justified by the company's recent earnings volatility and membership challenges, but it also presents potential value if the turnaround succeeds. Historically, Centene's PS ratio has ranged from 0.32x (Q1 2026) to 1.48x (Q4 2021). The current PS of 0.10x is near the bottom of its historical band, suggesting the stock is cheap relative to its own history. This low valuation reflects the market's skepticism about earnings recovery, but it also implies that positive surprises could lead to multiple expansion.
PE
-3.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-4.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Centene's primary financial risk is earnings volatility, as evidenced by a swing from a -$6.63 billion net loss in Q3 2025 to a $1.54 billion profit in Q1 2026. The negative TTM net margin of -3.4% and ROE of -33.4% highlight the fragility of its profitability. While the debt-to-equity ratio of 0.94 is manageable, the company's reliance on government contracts exposes it to policy changes and membership fluctuations. The ACA membership slump, which triggered voluntary staff buyouts, underscores operational challenges in the exchange business.
Market & Competitive Risks: The stock's beta of 1.077 indicates slightly above-market volatility, making it sensitive to macro shifts. Trading at a PS ratio of 0.10x—an 80% discount to the industry average—the market is pricing in significant skepticism, but any negative surprise could lead to further multiple compression. Competitive risks include pressure from larger players like UnitedHealth and Humana in Medicare Advantage, and regulatory risks from potential changes to Medicaid funding or ACA subsidies. The recent CMS Medicare payment increase is a positive, but future policy shifts remain a wildcard.
Worst-Case Scenario: If Centene's margin improvement stalls, membership losses accelerate, or another large impairment occurs, the stock could retest its 52-week low of $25.08. From the current price of $66.44, this represents a potential downside of -62.2%. This scenario would likely involve a combination of ACA membership declines, adverse regulatory changes, and a loss of investor confidence, leading to a re-rating back to historical trough valuations.
